source
- AstraZeneca reportedly bids $10 billion for metabolic biotech Rhythm PharmaceuticalsAstraZeneca is said to have made a $10 billion offer to acquire Rhythm Pharmaceuticals, a biotech that develops treatments for rare neuroendocrine disorders. The proposal values Rhythm at $124 per…
- Novartis reports nine tumor cases in patients treated with Zolgensma gene therapyNovartis has confirmed that nine cases of tumors have been reported in patients who received its spinal muscular atrophy gene therapy, Zolgensma. The company says two cases are confirmed and seven…